TacticScaleWhat Indivior Pharmaceuticals Does & How It Makes Money (INDV)
Updated October 2026 · reflects Indivior Pharmaceuticals's latest reported financials
Specialty pharma company making buprenorphine treatments for opioid addiction. It earns revenue by manufacturing and selling branded buprenorphine prescription drugs, led by SUBLOCADE injections and SUBOXONE Film, mainly in the United States and also in Europe, Canada, Australia and other markets.
How Indivior Pharmaceuticals makes money
It earns revenue by manufacturing and selling branded buprenorphine prescription drugs, led by SUBLOCADE injections and SUBOXONE Film, mainly in the United States and also in Europe, Canada, Australia and other markets.
What Indivior Pharmaceuticals does
Indivior Pharmaceuticals is a specialty drugmaker focused on substance use disorders, especially opioid use disorder (OUD). Its products are built on buprenorphine. The main marketed products are SUBLOCADE, a monthly extended-release injection, and SUBOXONE Film, a buprenorphine-naloxone film that dissolves under the tongue. It also makes SUBOXONE and SUBUTEX tablets. The company sells in the United States, Europe, Canada, Australia and other international markets. Its pipeline includes INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 trials for moderate to severe OUD, and INDV-6001, a long-acting buprenorphine injectable being developed with Alar Pharmaceuticals. The company was incorporated in 2014 as Indivior PLC, took the name Indivior Pharmaceuticals, Inc. in January 2026, and is headquartered in North Chesterfield, Virginia.
Products & services
- SUBLOCADE
- SUBOXONE Film
- SUBOXONE Tablet
- SUBUTEX Tablet
- INDV-2000 (pipeline)
- INDV-6001 (pipeline)
What is Indivior Pharmaceuticals worth?
On an owner-earnings DCF, Indivior Pharmaceuticals's most-likely value is about $53 versus a recent price near $36 (47% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$24) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Alkermes (ALKS) · Neurocrine Biosciences (NBIX) · AbbVie (ABBV) · Collegium Pharmaceutical (COLL) · ANI Pharmaceuticals (ANIP)